Vedolizumab (Entyvio)

Covered for adults with moderately to severely active ulcerative colitis or Crohn’s disease only for FDA‑approved indications (off‑label uses excluded). Initial approval requires indication‑specific prior therapy trials (UC: ≥2‑month trial or intolerance to at least one systemic agent including a biologic; CD: trial of a biologic OR one conventional systemic therapy OR current/prior systemic corticosteroids or documented contraindication), prescription by or consultation with a gastroenterologist, dosing of 300 mg IV at weeks 0, 2, 6 then every 8 weeks, initial approval ~14 weeks, and renewals up to 12 months only with documented clinical response.

"Re-authorization limited to patients who have demonstrated response to Entyvio therapy."

Sign up to see full coverage criteria, indications, and limitations.